Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD. Fernandez-Saez EM, Losarcos M, Becerril S, Valenti V, et al. Metabolism 2023 Jul 28:155663. doi: 10.1016/j.metabol.2023.155663.

Read + Share

Amedeo Smart

Independent Medical Education

Fernandez-Saez EM, Losarcos M, Becerril S, Valenti V, et al. Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD. Metabolism 2023 Jul 28:155663. doi: 10.1016/j.metabol.2023.155663.
PMID: 37517791